菲图西兰可以减少X因子缺乏的小鼠的出血
Sebastien Verhenne1, Geneviève McCluskey1, Hortense Maynadié1,2
1Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITh U1176, Le Kremlin-Bicêtre, France.
Blood
|April 15, 2024
概括
菲图西兰 (Fitusiran) 是一种正在研究中的疗法,它通过降低抗血素水平来治疗X因子缺乏症. 这种方法改善了这种罕见的出血障碍的临床前模型中的血栓生成和血液静止.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- X因子 (FX) 缺乏症是一种罕见的出血障碍,其特点是血栓生成受损,出血风险增加.
- 目前的治疗方法通常涉及FX替代疗法,这可能受到供应和管理挑战的限制.
研究的目的:
- 为了研究fitusiran的治疗潜力,一个小的干扰RNA向抗血素,用于管理X因子缺乏.
- 评估降低FX缺乏症在临床前模型中降低抗血水平在增强血静中的有效性.
主要方法:
- 开发了一种具有严重X因子缺乏症的新型诱导性小鼠模型 (f10流小鼠) 具有<1%的FX活性.
- 使用体外凝血试验 (PT,aPTT),血栓生成试验和体内出血模型 (尾巴剪贴,沙静脉穿刺) 评估静血功能.
- 在f10流小鼠中评估菲图西兰治疗,测量抗血栓活性,血栓生成和出血参数.
主要成果:
- 与对照小鼠相比,f10流小鼠表现出明显延长的凝血时间,严重减少的血栓生成,以及增加的出血倾向.
- 在f10流小鼠中,菲图西兰治疗导致抗血栓活性降低,血栓生成增加,并在沙芬静脉穿刺出血模型中改善血静.
- 在f10流小鼠中,通过输注纯化的FX来纠正出血,验证了模型和FX的作用.
结论:
- 这项研究表明,通过菲图西兰降低抗血水平可以增强血生成,并在X因子缺乏的情况下改善静血潜力.
- 这些临床前数据支持针对抗血素作为X因子缺乏症和潜在的其他出血疾病的新疗法战略的潜力.
- 开发的诱导性FX缺陷模型是未来血液静止和血栓形成研究的一个有价值的工具.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
01:16Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.4K